Geneticists' desire to track the roots of complex diseases has shaken up the market for gene chips. Meredith Wadman reports on two firms jostling for position in a business potentially worth US$500 million.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Making the most of microarrays
Genomics: SNPs and human disease
Microarray Quality Control web focus
Related external links
Rights and permissions
About this article
Cite this article
The chips are down. Nature 444, 256–257 (2006). https://doi.org/10.1038/444256a
Published:
Issue Date:
DOI: https://doi.org/10.1038/444256a
This article is cited by
-
In brief
Nature (2006)
